Tuesday, March 31, 2020

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.

from Moneycontrol Business News https://ift.tt/3azKKTG
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

What made Putin sell 22,000 kg gold from Russia this year?

Russia’s central bank has sold 21.8 tonnes or 22,000 kilograms of gold so far in 2026 to help fund the country’s widening budget deficit, wh...